Eiken Chemical Co (TSE:4549) ROE %: -0.13% (As of Mar. 2026)


TSE:4549 Eiken Chemical Co Ltd TSE:4549
81 GF Score
Price 円2,525.00
GF Value 円2,477.93
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Eiken Chemical Co ROE %?

Eiken Chemical Co TSE:4549 +1.45% 81 ROE % is -0.13% as of Mar. 2026. GuruFocus rates TSE:4549 with a GF Score™ of 81/100 and a GF Value™ of 円2,477.93 (Fairly Valued). The stock has 4 warning signs investors should review. Among 798 Medical Devices & Instruments companies, Eiken Chemical Co ranks better than 69.3% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Eiken Chemical Co's annualized net income for the quarter that ended in Mar. 2026 was 円-56 Mil. Eiken Chemical Co's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was 円43,889 Mil. Therefore, Eiken Chemical Co's annualized ROE % for the quarter that ended in Mar. 2026 was -0.13%.

The historical rank and industry rank for Eiken Chemical Co's ROE % or its related term are showing as below:

TSE:4549' s ROE % Range Over the Past 10 Years
Min: 4.98   Med: 9.86   Max: 14.22
Current: 8.54

During the past 13 years, Eiken Chemical Co's highest ROE % was 14.22%. The lowest was 4.98%. And the median was 9.86%.

TSE:4549's ROE % is ranked better than
69.3% of 798 companies
in the Medical Devices & Instruments industry
Industry Median: 2.41 vs TSE:4549: 8.54

Eiken Chemical Co  (TSE:4549) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-56/43889
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-56 / 42088)*(42088 / 61433)*(61433 / 43889)
=Net Margin %*Asset Turnover*Equity Multiplier
=-0.13 %*0.6851*1.3997
=ROA %*Equity Multiplier
=-0.09 %*1.3997
=-0.13 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-56/43889
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-56 / 412) * (412 / 560) * (560 / 42088) * (42088 / 61433) * (61433 / 43889)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= -0.1359 * 0.7357 * 1.33 % * 0.6851 * 1.3997
=-0.13 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Eiken Chemical Co ROE % Related Terms


Eiken Chemical Co ROE % Historical Data

* Premium members only.

The historical data trend for Eiken Chemical Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiken Chemical Co ROE % Chart

Eiken Chemical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.22 12.03 5.52 4.98 8.46

Eiken Chemical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 5.62 22.21 6.78 -0.13

TSE:4549 vs ABT, SYK, MDT: ROE % Comparison

For the Medical Devices subindustry, Eiken Chemical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eiken Chemical Co ROE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eiken Chemical Co's ROE % distribution charts can be found below:

* The bar in red indicates where Eiken Chemical Co's ROE % falls into.


TSE:4549
81GF Score
Eiken Chemical Co Ltd TSE:4549
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eiken Chemical Co ROE % Calculation

Eiken Chemical Co's annualized ROE % for the fiscal year that ended in Mar. 2026 is calculated as

ROE %=Net Income (A: Mar. 2026 )/( (Total Stockholders Equity (A: Mar. 2025 )+Total Stockholders Equity (A: Mar. 2026 ))/ count )
=3708/( (43596+44033)/ 2 )
=3708/43814.5
=8.46 %

Eiken Chemical Co's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-56/( (43745+44033)/ 2 )
=-56/43889
=-0.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -0.13% mean?
Eiken Chemical Co (TSE:4549) has a ROE % of -0.13% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Eiken Chemical Co and its competitors. Over the past decade, Eiken Chemical Co's ROE % has ranged from 4.98 to 14.22. According to the industry distribution chart, Eiken Chemical Co ranks #245 out of 798 companies in the Medical Devices & Instruments industry, placing it in the top 30.7%.
Is Eiken Chemical Co's ROE % too high?
Eiken Chemical Co's current ROE % is -0.13%. Over the past 10 years, this metric has ranged from a low of 4.98 to a high of 14.22. Based on the distribution chart, Eiken Chemical Co ranks #245 out of 798 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Eiken Chemical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eiken Chemical Co's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Eiken Chemical Co ranks #245 out of 798 companies for ROE %. This puts Eiken Chemical Co in the upper half of its industry. The industry median ROE % is 2.41. Historically, Eiken Chemical Co's own ROE % has ranged from 4.98 to 14.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.41, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Eiken Chemical Co and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eiken Chemical Co's current ROE % is -0.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiken Chemical Co stock overvalued right now?
Based on GuruFocus' analysis, Eiken Chemical Co (TSE:4549) is currently considered Fairly Valued. The stock's GF Value™ is 円2,477.93, compared to a current price of 円2,525.00 — trading 1.9% above its estimated fair value. The current ROE % is -0.13%. Eiken Chemical Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Eiken Chemical Co (TSE:4549), the current ROE % is -0.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eiken Chemical Co (TSE:4549) Overvalued in 2026?

Based on GuruFocus' analysis, Eiken Chemical Co stock appears to be overvalued. The current stock price of 円2,525.00 is trading 1.9% above its estimated GF Value™ of 円2,477.93. GuruFocus considers Eiken Chemical Co to be Fairly Valued.

Key valuation signals for TSE:4549:

  • ROE %: -0.13%
  • GF Value™: 円2,477.93 vs. price of 円2,525.00 (1.9% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the TSE:4549 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eiken Chemical Co Business Description

Address 4-19-9 Taito, Taito-ku, Tokyo, JPN, 110-8408
Eiken Chemical Co Ltd is a Japan-based company. It manufactures and sells clinical diagnostics and equipment. The company is engaged in processing, manufacture, purchase and sale of test agents, property and casualty insurance agency business. It as a general manufacturer of clinical diagnostics offers a wide range of in vitro diagnostic aids for all fields of medicine. Its major products include the Fecal immunochemical test, Molecular Genetics (LAMP), Microbiology, among many others.
81GF Score

Get the complete analysis for TSE:4549

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,525.00
Price
円2,477.93
GF Value